ArticleEuropean journal of nuclear medicine and molecular imaging2011

A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial).

Joyce M van Dodewaard-de Jong et al.PubMed ↗Publisher ↗

No numbers read from the abstract.